Today: 7 February 2026
Subscribe
Browse Category

NYSE:SYF News 15 October 2025 - 14 January 2026

Fiserv stock edges up as Clover lands CareCredit expansion — here’s what traders watch next

Fiserv stock edges up as Clover lands CareCredit expansion — here’s what traders watch next

New York, January 14, 2026, 15:08 EST — Regular session Fiserv shares edged up Wednesday afternoon, hitting $66.81, even as the S&P 500 ETF slipped roughly 0.8%. The move was modest, yet the situation remains fragile. Fiserv is working to regain trust after slashing its outlook and shaking up leadership in October, which sparked a record one-day plunge in its stock. Broader markets dragged lower again. Wall Street’s key indexes dropped for a second day while investors digested patchy results from major banks. “It’s not unusual to see a little bit of a pullback,” said Jake Johnston, deputy CIO at
14 January 2026
········
American Express stock sinks after Trump’s 10% credit-card rate cap idea — what AXP investors watch next

American Express stock sinks after Trump’s 10% credit-card rate cap idea — what AXP investors watch next

New York, Jan 12, 2026, 17:50 ET — Trading after hours. American Express shares fell 4.3% in after-hours trading Monday, following President Donald Trump’s call for a one-year cap on credit card interest rates at 10%. The stock last changed hands at $359.59, down $16.10 from its previous close, after dipping as low as $355.50 earlier in the session. (Reuters) The concern is straightforward: card lenders earn big when users carry balances, and a strict cap would quickly crush those profits. The selloff dragged down the entire credit sector, with Synchrony Financial, Bread Financial, and Capital One sliding 8% to
13 January 2026
·······
Capital One stock drops on Trump’s 10% credit-card rate cap talk as $425 million depositor settlement advances

Capital One stock drops on Trump’s 10% credit-card rate cap talk as $425 million depositor settlement advances

New York, Jan 12, 2026, 16:33 EST — After-hours Shares of Capital One Financial dropped 6.4% to $233.20 in after-hours trading Monday, dragged down by a widespread selloff among credit-card lenders. The slide followed President Donald Trump’s call to impose a 10% cap on credit-card interest rates for one year. (Reuters) The proposal targets Capital One’s main revenue driver: interest on revolving credit-card balances. It comes as the company grapples with new developments in a long-standing fight with depositors over interest rates on certain savings accounts. (Reuters) On Friday, Trump urged for the cap to start on Jan. 20 but
12 January 2026
········
Synchrony Financial stock slides on Trump’s 10% credit-card rate cap pitch — what investors watch next

Synchrony Financial stock slides on Trump’s 10% credit-card rate cap pitch — what investors watch next

New York, Jan 12, 2026, 3:33 PM EST — Regular session Shares of Synchrony Financial dropped sharply on Monday, tumbling 8.2% to $79.76 in afternoon trading. The slide followed President Donald Trump’s push for a one-year cap on credit-card interest rates at 10%, a move investors warn could severely tighten card lending profits. (Reuters) The proposal is significant since interest income drives card issuers’ profits, yet the cap is set well below prevailing rates. The Federal Reserve reported the average credit-card interest rate at 20.97% in November, highlighting just how steep a 10% limit would be. (Reuters) Trump announced the
12 January 2026
····
Bread Financial (BFH) stock slides on Trump’s 10% credit-card rate cap push; what’s next

Bread Financial (BFH) stock slides on Trump’s 10% credit-card rate cap push; what’s next

New York, Jan 12, 2026, 15:08 EST — Regular session Bread Financial Holdings’ shares dropped 10.8% to $71.65 in afternoon trading Monday, hitting a low of $70.06 earlier in the session. The move came after President Donald Trump proposed capping credit card interest rates at 10% for one year, beginning Jan. 20. However, Trump didn’t explain how he would enforce compliance among companies. (Reuters) Why it matters now: Credit cards function as “revolving credit,” letting borrowers carry balances and pay them off gradually. Issuers depend on interest income both to cover defaults and to finance perks. Truist Securities cautioned that
12 January 2026
·······
Synchrony Financial stock slides on Trump’s 10% credit-card rate cap push — what to know now

Synchrony Financial stock slides on Trump’s 10% credit-card rate cap push — what to know now

NEW YORK, Jan 12, 2026, 09:51 EST — Regular session Synchrony Financial shares were down about 7% at $80.80 on Monday morning, as investors sold credit-card lenders after President Donald Trump called for a one-year cap on credit-card interest rates. The proposal matters for Synchrony because it leans heavily on interest income from store and co-branded cards. A hard cap would compress what lenders earn on revolving balances, just as the sector heads into a fresh earnings cycle. Trump said on Friday he was calling for a 10% cap starting Jan. 20, but offered no details on how the plan
12 January 2026
····
Capital One stock slides as Trump’s 10% credit-card rate cap spooks lenders

Capital One stock slides as Trump’s 10% credit-card rate cap spooks lenders

New York, Jan 12, 2026, 08:13 EST — Premarket Shares of Capital One Financial dropped roughly 10% in premarket Monday after investors offloaded credit-card and consumer-lending stocks amid fresh chatter about rate caps. The squeeze landed hard on a business built around spreads. Credit-card interest powers issuer profits, and a 10% cap would plunge well below the industry’s current rates. The bids quickly evaporated. Synchrony Financial and Bread Financial tumbled between 10% and 11% in early trading. American Express slipped about 4%, while Visa and Mastercard each dropped roughly 2%. On the flip side, alternative lenders gained ground: Affirm rose
12 January 2026
············
US stocks today: Futures slip as Powell indictment threat roils banks; Fed speakers, Treasury auctions on the calendar

US stocks today: Futures slip as Powell indictment threat roils banks; Fed speakers, Treasury auctions on the calendar

New York, Jan 12, 2026, 07:52 EST — Premarket S&P 500 E-minis, the futures linked to the benchmark index, slipped 0.66% to 6,959 points by 5:51 a.m. ET. Dow E-minis were down 0.72%, while Nasdaq 100 E-minis declined 0.88%, market data showed. https://www.reuters.com/business/finance/wall-st-futures-slip-worries-over-fed-independence-financial-stocks-slide-2026-01-12/ The market’s focused on politics and positioning this morning, not just the economic data. Traders face a packed week ahead with bank earnings and an inflation report on the docket. Now, the Fed chair has emerged as a standalone headline risk. https://www.reuters.com/business/finance/global-markets-view-usa-2026-01-12/ Federal Reserve Chair Jerome Powell revealed that the Justice Department issued grand jury subpoenas to
12 January 2026
············
Synchrony Financial Stock Surges on Blowout Q3 Earnings and $1B Buyback Plan

Synchrony Financial Stock Surges on Blowout Q3 Earnings and $1B Buyback Plan

Synchrony Financial’s stock has rallied on these strong fundamentals. After closing near $72.84 on Oct. 14, shares ticked up in early trading on Oct. 15 (around $74) as investors digested the blowout results reuters.com marketbeat.com. The company’s Q3 beat was driven by tighter credit management and robust online spending, giving shareholders confidence. “Synchrony’s third-quarter performance was highlighted by a return to purchase volume growth… and continued strength in our credit performance,” said CEO Brian Doubles benzinga.com, echoing industry-wide trends of healthy consumer payments. The earnings report showed earnings per share of $2.86, well above the $2.22 analysts expected marketbeat.com finimize.com.
15 October 2025
····

Stock Market Today

GSK share price set for Monday watch after EU clears Nucala COPD use

GSK share price set for Monday watch after EU clears Nucala COPD use

7 February 2026
GSK shares closed Friday up 0.83% at a 52-week high after the EU approved Nucala for certain uncontrolled COPD patients. Insider filings showed chairman Jonathan Symonds bought 2,500 shares while executive David Redfern sold 100,000. The FTSE 100 rose 0.6%. Broker ratings on GSK remained mixed.
Go toTop